These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 38171842)
1. [Pharmacological characteristics and clinical outcomes of Epcoritamab (recombinant) (Epkinly Takaura K; Ando H; Ganoza ER Nihon Yakurigaku Zasshi; 2024; 159(1):61-68. PubMed ID: 38171842 [TBL] [Abstract][Full Text] [Related]
2. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Hutchings M; Mous R; Clausen MR; Johnson P; Linton KM; Chamuleau MED; Lewis DJ; Sureda Balari A; Cunningham D; Oliveri RS; Elliott B; DeMarco D; Azaryan A; Chiu C; Li T; Chen KM; Ahmadi T; Lugtenburg PJ Lancet; 2021 Sep; 398(10306):1157-1169. PubMed ID: 34508654 [TBL] [Abstract][Full Text] [Related]
3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
4. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma. Izutsu K; Kumode T; Yuda J; Nagai H; Mishima Y; Suehiro Y; Yamamoto K; Fujisaki T; Ishitsuka K; Ishizawa K; Ikezoe T; Nishikori M; Akahane D; Fujita J; Dinh M; Soong D; Noguchi H; Buchbjerg JK; Favaro E; Fukuhara N Cancer Sci; 2023 Dec; 114(12):4643-4653. PubMed ID: 37921363 [TBL] [Abstract][Full Text] [Related]
5. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Linton KM; Vitolo U; Jurczak W; Lugtenburg PJ; Gyan E; Sureda A; Christensen JH; Hess B; Tilly H; Cordoba R; Lewis DJ; Okada C; Hutchings M; Clausen MR; Sancho JM; Cochrane T; Leppä S; Chamuleau MED; Gernhardt D; Altıntaş I; Liu Y; Ahmadi T; Dinh MH; Hoehn D; Favaro E; Elliott B; Thieblemont C; Vose JM Lancet Haematol; 2024 Aug; 11(8):e593-e605. PubMed ID: 38889737 [TBL] [Abstract][Full Text] [Related]
6. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. van der Horst HJ; de Jonge AV; Hiemstra IH; Gelderloos AT; Berry DRAI; Hijmering NJ; van Essen HF; de Jong D; Chamuleau MED; Zweegman S; Breij ECW; Roemer MGM; Mutis T Blood Cancer J; 2021 Feb; 11(2):38. PubMed ID: 33602901 [TBL] [Abstract][Full Text] [Related]
7. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. Thieblemont C; Phillips T; Ghesquieres H; Cheah CY; Clausen MR; Cunningham D; Do YR; Feldman T; Gasiorowski R; Jurczak W; Kim TM; Lewis DJ; van der Poel M; Poon ML; Cota Stirner M; Kilavuz N; Chiu C; Chen M; Sacchi M; Elliott B; Ahmadi T; Hutchings M; Lugtenburg PJ J Clin Oncol; 2023 Apr; 41(12):2238-2247. PubMed ID: 36548927 [TBL] [Abstract][Full Text] [Related]
8. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Bannerji R; Arnason JE; Advani RH; Brown JR; Allan JN; Ansell SM; Barnes JA; O'Brien SM; Chávez JC; Duell J; Rosenwald A; Crombie JL; Ufkin M; Li J; Zhu M; Ambati SR; Chaudhry A; Lowy I; Topp MS Lancet Haematol; 2022 May; 9(5):e327-e339. PubMed ID: 35366963 [TBL] [Abstract][Full Text] [Related]
9. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978 [TBL] [Abstract][Full Text] [Related]
10. Epcoritamab: First Approval. Frampton JE Drugs; 2023 Sep; 83(14):1331-1340. PubMed ID: 37597091 [TBL] [Abstract][Full Text] [Related]
11. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619 [TBL] [Abstract][Full Text] [Related]
12. Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial. Matasar M; Bartlett NL; Shadman M; Budde LE; Flinn I; Gregory GP; Kim WS; Hess G; El-Sharkawi D; Diefenbach CS; Huang H; To I; Parreira J; Wu M; Kwan A; Assouline S Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):240-253. PubMed ID: 38195322 [TBL] [Abstract][Full Text] [Related]
13. Semimechanistic Physiologically-Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B-Cell Lymphomas. Li T; Hiemstra IH; Chiu C; Oliveri RS; Elliott B; DeMarco D; Salcedo T; Egerod FL; Sasser K; Ahmadi T; Gupta M Clin Pharmacol Ther; 2022 Nov; 112(5):1108-1119. PubMed ID: 35996883 [TBL] [Abstract][Full Text] [Related]
14. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment. Bock AM; Nowakowski GS; Wang Y Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296 [TBL] [Abstract][Full Text] [Related]
15. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial. Buhmann R; Michael S; Juergen H; Horst L; Peschel C; Kolb HJ J Transl Med; 2013 Jul; 11():160. PubMed ID: 23815981 [TBL] [Abstract][Full Text] [Related]
17. Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated With Epcoritamab. Phillips T; Lugtenburg P; Kalsekar A; Mutebi A; Wang A; Blaedel J; Kosa K; Martin S; Sacchi M; Kilavuz N; Thieblemont C Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):e78-e87.e2. PubMed ID: 38151388 [TBL] [Abstract][Full Text] [Related]
18. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. Michot JM; Bouabdallah R; Vitolo U; Doorduijn JK; Salles G; Chiappella A; Zinzani PL; Bijou F; Kersten MJ; Sarmiento R; Mosulen S; Mendez C; Uttamsingh S; Pourdehnad M; Hege K; Chen T; Klein C; Hagner PR; Nikolova Z; Ribrag V Lancet Haematol; 2020 Sep; 7(9):e649-e659. PubMed ID: 32758434 [TBL] [Abstract][Full Text] [Related]
19. Translational findings for odronextamab: From preclinical research to a first-in-human study in patients with CD20+ B-cell malignancies. Zhu M; Olson K; Kirshner JR; Khaksar Toroghi M; Yan H; Haber L; Meagher C; Flink DM; Ambati SR; Davis JD; DiCioccio AT; Smith EJ; Retter MW Clin Transl Sci; 2022 Apr; 15(4):954-966. PubMed ID: 34997701 [TBL] [Abstract][Full Text] [Related]
20. CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting. Liu X; Zhao J; Guo X; Song Y J Hematol Oncol; 2023 Aug; 16(1):90. PubMed ID: 37537626 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]